@clakr_up's MK-677 claims need a reality check

What did @clakr_up actually say?

The transcript from this video doesn't actually contain any coherent claims about MK-677. The audio captured appears to be song lyrics or background music, not the creator speaking directly. So we're working primarily from the caption, which states they started taking MK-677 a month ago, "felt the difference," and claim they "don't look natty anymore." That's what we can actually fact-check here.

To be clear: the caption is the claim. The creator says they chose MK-677 because they were "sick of not seeing results right away." That framing, impatience driving compound use, is worth examining honestly, because it's exactly the mindset the supplement and grey-market peptide industry depends on.

Does the science back this up?

MK-677 (ibutamoren) does have real pharmacological effects. It's a ghrelin receptor agonist that stimulates growth hormone secretion and raises IGF-1 levels. That part is not in dispute. Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) confirmed it meaningfully increases GH pulse amplitude and IGF-1 in healthy adults.

Whether those hormonal changes translate into visible body composition changes in one month is a different question. A 2008 study by Nass et al. in the Annals of Internal Medicine looked at MK-677 in older adults over two years and found increased lean mass but also significant water retention and elevated fasting glucose. That water retention is important context. A lot of what people perceive as "looking less natty" in the first weeks is likely extracellular fluid, not muscle tissue. The timeline here, one month, is too short to confidently separate real hypertrophy from fluid shifts.

What did they get wrong (or right)?

The creator gets partial credit for transparency. Saying "I haven't been honest" and disclosing compound use to an audience is more than most creators do. That matters.

What's more problematic is the framing that impatience justified the decision, and the implied message that visible changes after one month validate the choice. Here's the issue: MK-677 is not approved by the FDA for performance or body composition purposes. It's been studied primarily in growth hormone deficiency and muscle wasting conditions. Using it as a shortcut for gym results sits outside what the clinical evidence was designed to support.

The "don't look natty anymore" claim is also doing a lot of work. One month in, with MK-677's known water retention effects, what you're likely seeing is not the anabolic result the creator implies. Elevated hunger (MK-677 is a ghrelin mimetic, meaning it will make you hungrier) also complicates body composition readings early on.

• Water retention is a well-documented short-term effect (Nass et al., 2008)
• IGF-1 elevation is real but body composition changes take longer to manifest as visible muscle
• Ghrelin agonism increases appetite, which can work against body composition goals

What should you actually know?

MK-677 is not a peptide in the strict sense. It's a small molecule compound, often miscategorized alongside peptides like ipamorelin or CJC-1295. That distinction matters because its mechanism, half-life, and side effect profile differ from injectable GH secretagogues.

Known side effects from clinical literature include increased appetite, fasting glucose elevation, water retention, and in some studies, increased cortisol. Murphy et al. (1998, European Journal of Endocrinology) documented appetite increases of roughly 20% in subjects taking ibutamoren. For someone trying to improve body composition, that's not a neutral side effect.

There's also no regulatory framework for sourcing MK-677 through grey-market channels, which is how most people obtain it. Purity, dosing accuracy, and contamination are genuine concerns that no influencer disclosure changes.

If growth hormone optimization is a real clinical goal for you, there are supervised, evidence-based paths. A one-month TikTok update is not a substitute for bloodwork, IGF-1 monitoring, or a conversation with a licensed provider.